首发精神病缓解后早期减量或停药与维持抗精神病药的随机临床试验
HAMLETT 研究在荷兰 26 个精神病专科单位纳入 347 例首发精神病缓解期患者,随机分为 12 个月内早期减量或停药组与 12 个月维持治疗组,比较 4 年结局。早期减量或停药组第一年复发风险更高、生活质量更差,但第 3 年和第 4 年研究者评定的整体功能更优,症状严重度呈相似趋势。
要点
- 早期减量或停药第一年复发风险升高(OR 2.84),生活质量更低。
- 第 3、4 年减量或停药组研究者评定整体功能显著更优。
- 减量或停药组出现 3 例确认自杀死亡,维持组 1 例。
核心结论
- 早期减量或停药第一年带来复发和生活质量风险,但第 3、4 年研究者评定功能更优,症状严重度呈相似趋势。
- 因两组从 1 年起抗精神病药剂量相当,后期功能优势可能反映患者学会了更好地使用药物应对精神病易感性,而非直接源于更低剂量。
- 早期减量或停药的潜在学习和赋权要素需与短期风险谨慎权衡。
研究设计与样本
- HAMLETT 研究为单盲实用性随机(1:1)临床试验,在荷兰 26 个精神病专科单位于 2017 年 9 月至 2023 年 3 月开展。
- 纳入首发精神病缓解期患者,共 347 例(241 例男性,69.5%;平均年龄 27.9 岁,SD 8.7),168 例随机至早期减量或停药组,179 例至维持治疗组。
- 干预为缓解后 12 个月内早期减量或停药,对照为 12 个月维持治疗。
主要发现
- 主要结局 WHODAS-2 未显示时间×分组交互作用。
- 严重不良事件和不良反应两组相似,但减量或停药组有 3 例确认自杀死亡,维持组有 1 例。
临床怎么用
- 对首发精神病缓解期患者考虑早期减量或停药时,需告知第一年复发风险升高和生活质量下降的可能。
- 早期减量或停药可能带来远期功能获益,但需与短期风险及自杀死亡信号谨慎权衡。
- 从 1 年起两组剂量相当时,后期功能优势可能反映患者学习管理药物的经验,而非单纯低剂量效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dose reduction or discontinuation (DRD) early after remission from first-episode psychosis (FEP) increases short-term relapse risk. Controversy remains regarding potential benefits in functioning over the longer term because studies with long-term outcomes show conflicting findings. OBJECTIVE: To compare short- and long-term effects between DRD and maintenance medication over a 4-year period in a large sample of patients with FEP. DESIGN, SETTING, AND PARTICIPANTS: The Handling Antipsychotic Medication Long-Term Evaluation of Targeted Treatment (HAMLETT) study is a single-blind pragmatic randomized (1:1) clinical trial conducted in 26 specialized psychosis units in the Netherlands from September 2017 to March 2023. Patients remitted for FEP from in- and outpatient services were included. INTERVENTIONS: DRD within 12 months after remission compared with 12 months maintenance treatment. MAIN OUTCOMES AND MEASURES: The primary outcome was patient-rated functioning, measured by the World Health Organization Disability Assessment Schedule 2.0 (WHODAS-2). Secondary outcomes were researcher-rated global assessment of functioning (GAF), quality of life, relapse, symptom severity (measured by the Positive and Negative Syndrome Scale [PANSS]), serious adverse events, and adverse effects. RESULTS: A total of 347 patients (241 male [69.5%]; mean [SD] age, 27.9 [8.7] years) were included, with 168 randomized to early DRD and 179 to maintenance. WHODAS-2 showed no time × condition interaction. In the first year, DRD was associated with higher risk of relapse (odds ratio, 2.84; 95% CI, 1.08 to 7.66; P = .04) and lower quality of life (β = -3.31; 95% CI, -6.34 to -0.29; P = .03). At 3 years (β = 3.61; 95% CI, 0.28 to 6.95; P = .03) and 4 years (β = 6.13; 95% CI, 2.03 to 10.22; P = .003), a nonlinear effect of time occurred, showing significantly better GAF for patients in the DRD condition, with a similar trend for PANSS at 4 years (P for trend = .06). Although SAEs and adverse effects were similar between groups, 3 confirmed deaths by suicide occurred in the DRD group, against 1 death by suicide in the maintenance group. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that DRD posed risks of relapse and worse quality of life over the first year but yielded better researcher-rated functioning at the third and fourth year, with a similar trend for symptom severity; because antipsychotic medication doses were comparable in the 2 groups from 1 year onwards, this finding is not a direct result of lower medication but may reflect a learning experience to use antipsychotics to better handle psychotic vulnerability. These findings suggest that the potential learning and empowering element of DRD needs to be weighed carefully against short-term risks. TRIAL REGISTRATION: EudraCT number: 2017-002406-12.
引用
- Sommer IE, de Beer F, Gangadin S, et al. Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode Remission: A Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 41032294. doi:10.1001/jamapsychiatry.2025.2525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。